Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies
Academic Article
Publication Date:
2020
Iris type:
1.1.2. Articolo in Rivista - Letter, Note
Keywords:
haematology; neuromuscular; neuropathy; neurophysiology; oncology; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Female; Guillain-Barre Syndrome; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Young Adult
List of contributors:
Fargeot, G.; Dupel-Pottier, C.; Stephant, M.; Lazarovici, J.; Thomas, L.; Mouthon-Reignier, C.; Riad, B.; Carde, P.; Berzero, G.; Tafani, C.; Nicolas, W.; Viala, K.; Maisonobe, T.; Lenglet, T.; Wang, A.; Magy, L.; Bihan, K.; Gaspar, N.; Adams, D.; Echaniz-Laguna, A.; Cauquil, C.; Psimaras, D.
Published in: